Mounjaro vs Zepbound: What's Actually Different?

Yes. Chemically, they are the same drug: tirzepatide, a once-weekly injectable made by Eli Lilly. Same molecule, same manufacturer, same dose strengths, same single-dose pen, same storage rules, same side effect profile.

What differs is the label on the box and the indication the FDA approved it for.

Mounjaro was approved in May 2022 for adults with type 2 diabetes, as an addition to diet and exercise to improve blood sugar control. Weight loss was observed in those trials, but glycemic control is the approved use.

Zepbound was approved in November 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. In December 2024 the FDA added a second indication: moderate-to-severe obstructive sleep apnea in adults with obesity.

This two-brand structure isn't unusual. Novo Nordisk does the same thing with semaglutide: Ozempic for diabetes, Wegovy for weight management, Rybelsus as the oral diabetes tablet. The regulatory pathway for a diabetes drug and a weight-management drug are separate, so companies run separate trial programs and file separate applications — which produces separate brands.

Tirzepatide itself is a dual agonist: it activates both GIP and GLP-1 receptors, the two gut hormones that signal fullness and regulate insulin. Semaglutide activates only the GLP-1 receptor. That mechanistic difference is covered in our [tirzepatide vs semaglutide comparison](/blog/tirzepatide-vs-semaglutide-surmount-5-head-to-head).

The headline number comes from SURMOUNT-1 (NEJM, 2022), which enrolled 2,539 adults with obesity or overweight without diabetes. Over 72 weeks, participants on the 15 mg dose lost an average of 20.9% of body weight. The 10 mg group lost 19.5%, and the 5 mg group lost 15.0%. Placebo was 3.1%.

For a person starting at 200 pounds, 20.9% is roughly 42 pounds.

Two caveats worth holding onto. First, those are averages — individual results ranged widely, and roughly a third of participants at the top dose lost 25% or more while others lost far less. Second, all participants received lifestyle counseling alongside the medication.

In people with type 2 diabetes, weight loss is consistently smaller. SURMOUNT-2 found about 14.7% average reduction at 15 mg over 72 weeks in adults with obesity and type 2 diabetes. This is a well-documented pattern across the whole GLP-1 class, not a flaw in the medication.

For sleep apnea, the SURMOUNT-OSA trials (NEJM, 2024) found tirzepatide reduced apnea-hypopnea index — the standard measure of breathing interruptions per hour — by roughly 25 to 29 events per hour, compared with about 5 on placebo. That result is what earned Zepbound its second indication.

And if your weight loss stalls partway through, that's expected physiology rather than failure. Our guide to [why GLP-1 weight loss plateaus](/blog/glp1-weight-loss-plateau-why-it-stalls-and-what-to-do) walks through what's actually happening.

This is the question that decides it for most people, and the answer usually comes down to your diagnosis.

If you have type 2 diabetes, Mounjaro is far more likely to be covered. Diabetes medications sit on standard formularies and most commercial plans include tirzepatide at some tier, usually with prior authorization requiring a documented type 2 diabetes diagnosis and often a trial of metformin first.

If you don't have diabetes, you need Zepbound — and coverage is genuinely difficult. Many employer plans carve out anti-obesity medications entirely as a category. Medicare Part D is statutorily prohibited from covering drugs used for weight loss, though it can cover Zepbound when prescribed for obstructive sleep apnea, which has been a meaningful workaround since the 2024 indication. Our [Medicare coverage guide](/blog/does-medicare-cover-glp1-weight-loss-drugs-2026) explains where that stands.

A few practical points:

• •You can't get Mounjaro prescribed for weight loss to game the formulary. Prior authorization for Mounjaro requires diabetes documentation — A1c values, diagnosis codes, sometimes prior medication history. Plans check.
• •Coverage denials are appealable, and appeals work more often than people expect. Our [prior authorization appeal guide](/blog/glp1-insurance-denial-how-to-appeal-prior-authorization-2026) covers the process step by step.
• •Cash-pay pricing has changed substantially. Lilly's direct-purchase program offers single-dose vials at prices well below the list price of the pens, and self-pay routes have broadened. See our [2026 direct-pay pricing breakdown](/blog/glp1-direct-pay-pricing-2026-lillydirect-novocare-trumprx) for current figures.
• •Savings cards are indication-specific. A Zepbound savings card doesn't apply to a Mounjaro prescription and vice versa.

One more thing that surprises people: if your plan covers one and not the other, the pharmacy cannot substitute. Even though the molecule is identical, they are separate NDC-coded products. Your prescriber has to write for the covered one.

Yes, and the switch is unusually simple because you're not changing drugs — you're changing labels.

Your dose transfers directly. If you're on Mounjaro 10 mg, you start Zepbound at 10 mg. There's no re-titration, no restarting at 2.5 mg, no washout period. Take your next weekly dose on schedule with the new pen.

The pens work identically. Same injection technique, same sites, same storage. If you were using the multi-dose Kwikpen versus single-dose pens, the mechanics differ slightly, but the medication doesn't.

Your side effects shouldn't change. Same molecule, same GI effects. If nausea, constipation, or fatigue improve or worsen after a switch, it's more likely coincidence or a dose change than the brand swap.

Why would you switch? Almost always insurance. Common scenarios:

• •You were on Mounjaro for diabetes, your A1c normalized, and your plan now questions the diabetes indication
• •Your employer added weight-management coverage at open enrollment, opening up Zepbound
• •You were diagnosed with obstructive sleep apnea, which opens a Zepbound pathway your plan will honor
• •One product is in shortage in your area and the other isn't

The reverse — being newly diagnosed with type 2 diabetes while on Zepbound — is less common but happens, and moving to Mounjaro often improves coverage.

One thing to plan for: don't let the switch create a gap. If you go more than about two weeks without a dose, you may need to restart titration, and the GI side effects come back. Get the new prescription filled before your last pen runs out. Our [missed dose timing guide](/blog/missed-glp1-dose-what-to-do-timing-guide) covers how much of a gap is tolerable.

Because it's the same drug, the side effect profile is identical. The most common in trials were gastrointestinal: nausea (about 25 to 30% at higher doses), diarrhea, constipation, and vomiting. Most were mild to moderate and concentrated during dose escalation rather than at steady state.

More serious but less common concerns include pancreatitis, gallbladder disease — gallstone risk rises with rapid weight loss — and thyroid C-cell tumors, which carry a boxed warning based on rodent studies. Tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Our [thyroid safety article](/blog/glp1-thyroid-safety-what-you-need-to-know) covers what that warning means and doesn't mean.

On duration: both are intended as long-term treatments, not courses. The SURMOUNT-4 trial made this concrete — participants who stopped tirzepatide after 36 weeks regained a substantial portion of lost weight over the following year, while those who continued kept losing. Obesity behaves like a chronic condition, and the medication manages rather than cures it.

For women in midlife, there's an additional layer. Muscle and bone loss during rapid weight loss compounds the losses already happening around menopause, which makes resistance training and protein intake more than optional. We cover this in [GLP-1s and bone density in menopause](/blog/glp1-bone-density-in-menopause-the-double-risk).

Whichever brand you end up on, the practical work is the same: get to an effective dose without wrecking your gut, protect your muscle, and keep the prescription filled.